



(12) Translation of
European patent specification

(11) NO/EP 3782612 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 9/20 (2006.01)
A61K 9/28 (2006.01)
A61K 31/7068 (2006.01)
A61P 1/00 (2006.01)
A61P 1/18 (2006.01)
A61P 7/00 (2006.01)
A61P 15/08 (2006.01)
A61P 35/00 (2006.01)
A61P 35/02 (2006.01)
A61P 43/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.01.22
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.11.08
(86)	European Application Nr.	20201143.3
(86)	European Filing Date	2009.05.14
(87)	The European Application's Publication Date	2021.02.24
(30)	Priority	2008.05.15, US, 5360908 P 2008.12.05, US, 20114508 P 2009.03.05, US, 15787509 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
(62)	Divided application	EP3692983, 2009.05.14
(73)	Proprietor	Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USA
(72)	Inventor	ETTER, Jeffrey B, 1318 Deer Train Rd., Boulder, CO Colorado 80302, USA LAI, Mei, 1038 Neon Forest Circle, Longmont, CO Colorado 80504, USA BACKSTROM, Jay T, 15400 Aberdeen St., Leawood, KS Kansas 66224, USA
(74)	Agent or Attorney	AWA NORWAY AS, Postboks 1052 Hoff, 0218 OSLO, Norge

(54)	Title	ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF
(56)	References Cited:	WO-A2-2008/028193 US-A1- 2004 186 065 WARD: "An oral dosage formulation of azacitidine: A pilot pharmacokinetic study", JOURNAL OF CLINICAL ONCOLOGY, vol. 25, no. 18S, 1 July 2007 (2007-07-01) , XP009121612, STOLTZ: "Development of an Oral Dosage Form of Azacitidine: Overcoming Challenges in Chemistry, Formulation, and Bioavailability", ASH ANNUAL MEETING, vol. 108, 1 January 2006 (2006-01-01), XP009121611,

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Farmasøytisk sammensetning omfattende en terapeutisk virksam mengde 5-azacytidin, for anvendelse i en fremgangsmåte ved behandling av et individ som har AML, hvor fremgangsmåten omfatter å oralt administrere den farmasøytiske sammensetning daglig i 14 eller flere dager, hvor sammensetningen er en sammensetning med umiddelbar frigivning og frigir 5-azacytidinet i det vesentlige i magen etter oral administrasjon til et individ.